Sol-Gel Technologies Ltd. Stock

$7.52

8.99% yesterday

Nasdaq, Jun 13, 10:16 pm CET

ISIN

IL0011417206

Symbol

SLGL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Sol-Gel Technologies Ltd. Stock price

$7.52

-72.98 90.66% 5Y

Nasdaq, Closing price Fri, Jun 13 2025

+0.62 8.99%

ISIN

IL0011417206

Symbol

SLGL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$19.22m
Enterprise Value	$2.33m
P/E (TTM) P/E ratio	negative
EV/Sales (TTM) EV/Sales	0.19
P/S ratio (TTM) P/S ratio	1.59
P/B ratio (TTM) P/B ratio	0.95
Revenue growth (TTM) Revenue growth	603.49%
Revenue (TTM) Revenue	$12.10m
EBIT (operating result TTM) EBIT	$-14.37m
Cash position	$16.89m
EPS (TTM) EPS	$-4.68
P/E forward	negative
P/S forward	1.99
EV/Sales forward	negative
Short interest	0.80%

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Get Started for Free Today

Sol-Gel Technologies Ltd. Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Sol-Gel Technologies Ltd.:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Sol-Gel Technologies Ltd.:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Sol-Gel Technologies Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	12 12	603% 603% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	5.17 5.17	28% 28% 43%
- Research and Development Expense	21 21	9% 9% 176%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-14 -14	42% 42% -119%
Net Profit	-13 -13	43% 43% -108%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Sol-Gel Technologies Ltd. Stock News

Neutral

GlobeNewsWire

●

22 days ago

Sol-Gel Reports First Quarter 2025 Results

NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025.

Neutral

GlobeNewsWire

●

about one month ago

Sol-Gel Announces Reverse Share Split

NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse Split”) of the Company's issued and outstanding ordinary shares, par value NIS 0.1 per share (the “Ordinary Shares”), at the ratio of 10-for-1, such that each ten (10) Ordinary Shares shall be con...

Neutral

GlobeNewsWire

●

about 2 months ago

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

Sol-Gel to receive $16 million during 2025 Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved Sol-G...

More Sol-Gel Technologies Ltd. News

Company Profile

Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.

Head office	Israel
CEO	Moshe Arkin
Employees	36
Founded	1997
Website	www.sol-gel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now